These stocks have one obvious thing in common.
News & Analysis: Nektar Therapeutics
NKTR earnings call for the period ending September 30, 2020.
NKTR earnings call for the period ending July 31, 2020.
NKTR earnings call for the period ending March 31, 2020.
New combination trials bring hope for patients and investors.
The biotech topped Wall Street estimates, but the real focus was on its pipeline.
NKTR earnings call for the period ending December 31, 2019.
In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.
The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.
Nektar Therapeutics' experimental opioid will finally get a long-awaited date with an FDA advisory committee -- and it probably won't go smoothly.